Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy

[1]  A. Abbruzzese,et al.  Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study , 2012, Journal of cellular and molecular medicine.

[2]  A. McDermott,et al.  The Therapeutic Potential of MicroRNAs: Disease Modulators and Drug Targets , 2011, Pharmaceutical Research.

[3]  J. Meyerhardt,et al.  A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[4]  L. Kvols,et al.  Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors , 2011, Journal of hematology & oncology.

[5]  D. Hanahan,et al.  Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition , 2011, Clinical Cancer Research.

[6]  J. Zavadil,et al.  Efficient in vivo microRNA targeting of liver metastasis , 2011, Oncogene.

[7]  J. Boudreaux.  Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS). , 2011, Endocrinology and metabolism clinics of North America.

[8]  R. Baum,et al.  Standard imaging techniques for neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[9]  Herb Chen,et al.  Hesperetin, a potential therapy for carcinoid cancer. , 2011, American journal of surgery.

[10]  L. Ellis,et al.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[12]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[13]  E. Raymond,et al.  Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. , 2010, Endocrinology and metabolism clinics of North America.

[14]  Herb Chen,et al.  Signaling mechanisms in neuroendocrine tumors as targets for therapy. , 2010, Endocrinology and metabolism clinics of North America.

[15]  B. Niederle,et al.  Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.

[16]  F. D. De Braud,et al.  Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. , 2010, Cancer treatment reviews.

[17]  A. Grossman,et al.  Paraneoplastic syndromes secondary to neuroendocrine tumours. , 2010, Endocrine-related cancer.

[18]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[19]  D. Coppola,et al.  NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor , 2010, Pancreas.

[20]  M. Milella,et al.  The mTOR pathway: a new target in cancer therapy. , 2010, Current cancer drug targets.

[21]  W. Oyen,et al.  Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  B. Eriksson.  New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? , 2010, Current opinion in oncology.

[23]  J. Mortensen,et al.  Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET , 2010, Journal of Nuclear Medicine.

[24]  E. Van Cutsem,et al.  90Y-edotreotide for metastatic carcinoid refractory to octreotide. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Valkema,et al.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.

[26]  Herb Chen,et al.  Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth , 2010, Molecular Cancer Therapeutics.

[27]  C. Ng,et al.  Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. , 2010, AJR. American journal of roentgenology.

[28]  A. Tolcher,et al.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  I. Modlin,et al.  Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours , 2009, Alimentary pharmacology & therapeutics.

[30]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide Therapy , 2009, Journal of Nuclear Medicine.

[32]  N. Ballian,et al.  A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[33]  M. Marra,et al.  Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. , 2009, Current cancer drug targets.

[34]  Herb Chen,et al.  Inhibition of Phosphatidylinositol 3-Kinase/Akt Signaling Suppresses Tumor Cell Proliferation and Neuroendocrine Marker Expression in GI Carcinoid Tumors , 2009, Annals of Surgical Oncology.

[35]  M. Cuggia,et al.  Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors , 2009, Journal of Nuclear Medicine.

[36]  K. Klose,et al.  Selective Internal Radiotherapy with Yttrium-90 Microspheres for Hepatic Metastatic Neuroendocrine Tumors: A Prospective Single Center Study , 2009, Digestion.

[37]  G. Vitale,et al.  Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. , 2009, American journal of physiology. Endocrinology and metabolism.

[38]  D. Polsky,et al.  Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor , 2009, Proceedings of the National Academy of Sciences.

[39]  I. Drozdov,et al.  Principal Component Analysis, Hierarchical Clustering, and Decision Tree Assessment of Plasma mRNA and Hormone Levels as an Early Detection Strategy for Small Intestinal Neuroendocrine (Carcinoid) Tumors , 2009, Annals of Surgical Oncology.

[40]  B. Skogseid,et al.  Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors , 2009, Neuroendocrinology.

[41]  G. Procopio,et al.  Activity of sunitinib in patients with advanced neuroendocrine tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Schmidt,et al.  Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[44]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[45]  M. Caplin,et al.  Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. , 2008, The American journal of cardiology.

[46]  K. Hess,et al.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Stridsberg,et al.  Tachykinins in endocrine tumors and the carcinoid syndrome. , 2008, European journal of endocrinology.

[48]  D. Morris,et al.  Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases , 2008, Cancer.

[49]  Derek Y. Chiang,et al.  High‐resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss , 2008, Genes, chromosomes & cancer.

[50]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Groves,et al.  Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG , 2008, Cancer.

[52]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[53]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Suzanne F. Jones,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  K. Hess,et al.  Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. Rashid,et al.  Allelic alterations in well‐differentiated neuroendocrine tumors (carcinoid tumors) identified by genome‐wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors , 2008, Genes, chromosomes & cancer.

[57]  A. Scarpa,et al.  Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary , 2007, Neuroendocrinology.

[58]  B. Kos-Kudła,et al.  Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin , 2007, Neuroendocrinology.

[59]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[60]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[61]  J. Tabernero,et al.  Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. , 2007, Endocrine-related cancer.

[62]  B. Skogseid,et al.  Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors , 2007, Clinical Cancer Research.

[63]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Anders Sundin,et al.  Nuclear imaging of neuroendocrine tumours. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[65]  F. Keleştimur,et al.  Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[66]  B. Wiedenmann,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about It , 2007, Neuroendocrinology.

[67]  L. Kvols,et al.  A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours , 2007, Expert opinion on investigational drugs.

[68]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[69]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[70]  I. Modlin,et al.  The functional characterization of normal and neoplastic human enterochromaffin cells. , 2006, The Journal of clinical endocrinology and metabolism.

[71]  I. Modlin,et al.  Therapeutic options for gastrointestinal carcinoids. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[72]  C. Charnsangavej,et al.  Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[73]  Jeffrey W. Clark,et al.  Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  K. Ahrar,et al.  Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors , 2005, Cancer.

[75]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[76]  R. Arnold,et al.  Endocrine tumours of the gastrointestinal tract: Chemotherapy. , 2005, Best practice & research. Clinical gastroenterology.

[77]  Douglas B. Evans,et al.  Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  J. Norton,et al.  Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. , 2004, Surgery.

[79]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[80]  H. Schmid,et al.  Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors , 2004, Neuroendocrinology.

[81]  Gregory Kaltsas,et al.  Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. , 2004, European journal of endocrinology.

[82]  A. Grossman,et al.  The diagnosis and medical management of advanced neuroendocrine tumors. , 2004, Endocrine reviews.

[83]  A. Jauch,et al.  Genetics of neuroendocrine and carcinoid tumours. , 2003, Endocrine-related cancer.

[84]  H. Gouya,et al.  CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. , 2003, AJR. American journal of roentgenology.

[85]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[86]  Bradford A. Moffat,et al.  Diffusion MRI: A New Strategy for Assessment of Cancer Therapeutic Efficacy , 2002, Molecular imaging.

[87]  J. Litz,et al.  Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. , 2002, Molecular cancer therapeutics.

[88]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[89]  M. Mignon.  Natural History of Neuroendocrine Enteropancreatic Tumors , 2000, Digestion.

[90]  S. Lipsitz,et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. , 1992, The New England journal of medicine.

[91]  L. Kvols,et al.  Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms , 1991, Cancer.

[92]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[93]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[94]  D. Coppola,et al.  Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated ( High-Grade ) Extrapulmonary Neuroendocrine Carcinomas , 2010 .

[95]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[96]  D. Bluemke,et al.  Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. , 2008, AJR. American journal of roentgenology.

[97]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[98]  R. Bale,et al.  Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007 .

[99]  G. Vitale,et al.  IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. , 2006, Cancer research.

[100]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  G. Vitale,et al.  IFN-β Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro , 2006 .

[102]  J. Taylor,et al.  BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. , 2005, Journal of endocrinological investigation.

[103]  L. Kvols,et al.  Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  K. Oberg.  Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  S. Baylin,et al.  Activated Raf-1 causes growth arrest in human small cell lung cancer cells. , 1998, The Journal of clinical investigation.